Recent Updates
Recently added Catalysts
PCRX Positive Sentiment Score: 70/100

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

Key Takeaway: Pacira BioSciences, Inc. (NASDAQ: PCRX) announced its participation in the 2024 Jefferies Global Healthcare Conference scheduled for June 6, 2024, in New York. The analyst-led fireside chat will focus on the company's ongoing commitment to providing non-opioid pain management solutions. Following the event, a replay of the audio webcast will be available on the company's website for two weeks. Pacira offers three commercial-stage non-opioid treatments designed to reduce opioid reliance.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira BioSciences is actively participating in the 2024 Jefferies Global Healthcare Conference.
  • The company is committed to providing non-opioid treatment options.
  • Pacira has three commercial-stage non-opioid treatments to manage pain.

Full Press Release Details

TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare Conference at 11:00 AM ET on Thursday, June 6, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.

Frequently Asked Questions

When will Pacira BioSciences participate in the Jefferies Conference?

Pacira BioSciences will join the Jefferies Global Healthcare Conference on June 6, 2024.

How can I access the live event audio?

Live audio can be accessed via the Events page on Pacira's website.

What is EXPAREL® used for?

EXPAREL® is a non-opioid treatment for postsurgical pain management.

What type of treatments does Pacira offer?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® as non-opioid treatments.

What is ioveraº®?

ioveraº® is a handheld device for drug-free pain control using cold therapy.

Last updated: May 30, 2024